Skip to content

TTRX TTRX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$295M+34.1%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$2.35B+1.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$2.68B+66.8%
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
$300.78M-0.4%

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M
Total equity$6.1M+647%
Total assets$18.6M

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M

Returns & leverage

See full
Return on equity-118.8%
Debt / equity
Current ratio2.2×

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's additional paid-in capital?
TTRX (TTRX) reported additional paid-in capital of $29.48M in Q1 2026.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.